Dual CAR-T Cell Therapy Drives Remission in Treatment-Refractory Lupus
A phase 1 trial targeting both CD19 and BCMA simultaneously achieved 80% remission in hard-to-treat lupus patients with no severe toxicities.
Summary
Researchers at Zhejiang University tested a novel dual CAR-T cell therapy in 15 patients with treatment-refractory systemic lupus erythematosus (SLE). By co-infusing T cells engineered to target both CD19-positive B cells and BCMA-positive long-lived plasma cells — two key sources of disease-driving autoantibodies — 80% of patients achieved both low disease activity and full remission criteria by week 12. Over a median follow-up of nearly two years, no dose-limiting toxicities or treatment deaths occurred. Cytokine release syndrome was mild (grade 1) in most patients, and common blood count suppression was reversible. Immune profiling confirmed elimination of harmful autoantibody-producing clones and restoration of healthy naive B cells, suggesting this approach may offer durable, potentially curative benefit for a historically difficult-to-treat population.
Detailed Summary
Systemic lupus erythematosus is a chronic autoimmune disease driven by self-reactive antibodies. While most patients respond to immunosuppressive drugs, a meaningful subset remains refractory, facing ongoing organ damage and poor quality of life. New therapeutic strategies are urgently needed for this group.
This phase 1 dose-escalation trial enrolled 15 patients (14 female, 1 male) with treatment-refractory SLE. The core innovation was co-infusing two types of autologous CAR-T cells: one targeting CD19 on circulating B cells, and one targeting BCMA on long-lived bone marrow plasma cells — both identified as major autoantibody sources in these patients. All patients received standard lymphodepletion with fludarabine and cyclophosphamide before infusion.
Over a median follow-up of 712 days, no dose-limiting toxicities occurred. Grade 1 cytokine release syndrome was the most common adverse event (87% of patients), with no neurotoxicity or deaths. Reversible hematologic side effects — neutropenia, thrombocytopenia, and anemia — were the most serious adverse events observed. Critically, 12 of 15 patients (80%) achieved both Lupus Low Disease Activity State and DORIS remission by week 12.
Multiomic analyses revealed elimination of autoreactive CD19+BCMA+ B cell clones, restoration of naive IgM/IgD B cells, and durable suppression of interferon and BAFF-driven inflammatory signatures — hallmarks of improved immune homeostasis. Three patients monitored for one full year showed sustained eradication of pathogenic clones, raising the possibility of functional cure.
While results are highly encouraging, the trial is small (n=15), single-arm, and conducted at a single institution, limiting generalizability. Longer follow-up and larger randomized trials are needed to confirm durability and comparative efficacy against existing therapies.
Key Findings
- 80% of patients achieved both LLDAS and DORIS remission by week 12 post-infusion.
- No dose-limiting toxicities, neurotoxicity, or treatment-related deaths over median 712-day follow-up.
- Grade 1 cytokine release syndrome occurred in 87% of patients; hematologic suppression was reversible.
- Multiomic profiling confirmed elimination of autoreactive B cell clones and restored naive B cell populations.
- Three patients showed sustained pathogenic clone eradication at 1 year, suggesting potential cure.
Methodology
Phase 1 open-label dose-escalation trial enrolling 15 treatment-refractory SLE patients who received co-infused autologous anti-CD19 and anti-BCMA CAR-T cells following fludarabine/cyclophosphamide lymphodepletion. Primary endpoints assessed dose-limiting toxicities and adverse events; secondary endpoints included remission criteria attainment and CAR-T persistence at 24 weeks. Multiomic immune profiling provided mechanistic insight.
Study Limitations
The trial enrolled only 15 patients at a single institution without a control arm, limiting statistical power and generalizability. Follow-up, while relatively long for a phase 1 study, is insufficient to confirm permanent remission or assess very late adverse events. Manufacturing autologous CAR-T cells is complex and costly, which may restrict accessibility if approved.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: